Latest news
- Business27 November 2023
Adalvo and Juno Canada sign licensing & supply agreement to commercialize a basket of products
Adalvo is pleased to announce that it has entered into a partnership with Juno Pharmaceuticals Canada, to commercialize a number of respiratory and dermatology dossiers. This licensing and supply agreement includes a basket...
- Business22 November 2023
Adalvo Announces Successful DCP Submission for Bosutinib Film-Coated Tablets
Adalvo is pleased to announce the successful DCP submission for Bosutinib 100, 400, 500mg film-coated tablets, indicated for the treatment of Chronic Myelogenous Leukemia. In 2022, this product achieved global sales...
- Business15 November 2023
Adalvo Announces Successful DCP Submission for Afatinib Film-Coated Tablets
Adalvo are pleased to announce the successful DCP submission for Afatinib 20, 30, 40, 50mg film-coated tablets. Based on the reference brand, GIOTRIF, Afatinib is indicated for the treatment of metastatic non-small cell...
- Business14 November 2023
Adalvo stands united in the fight against Diabetes
On this World Diabetes Day, Adalvo showcases the strides made in the realm of diabetic care. Rooted in our commitment to patient well-being, Adalvo stands as one of the leading B2B...
- Business08 November 2023
Adalvo announces successful DCP Submission for Riociguat Tablets
We are pleased to announce our successful DCP submission for Riociguat tablets. Based on the reference brand, Adempas, Riociguat is indicated for the treatment of adult patients with WHO Functional Class (FC) II...
- Business01 November 2023
Arphio and Adalvo Expand Access to Teduglutide
Adalvo, in collaboration with Arphio, is proud to introduce Teduglutide, a groundbreaking treatment addressing the urgent unmet needs of patients with Short Bowel Syndrome (SBS).
- Business17 October 2023
Countdown to CPhI 2023: One Week To Go
Adalvo is excited to remind you that CPhI Barcelona 2023 is just one week away! From October 24th to 26th, we will be part of this exceptional pharmaceutical event, and we've got...
- Business13 October 2023
Adalvo and Eurolab strengthen Strategic Partnership in South Africa and SSA Regions
Adalvo and Eurolab are pleased to announce the extension of their long-term strategic collaboration, signing a basket deal for three more products to be marketed and distributed in South Africa and as well as certain SSA...
- Business12 October 2023
Cladribine: Adalvo makes good progress on a challenging development
Adalvo is committed to delivering diversified and competitive assets, supporting our partners in every step of their journey. This is what positions Adalvo for success. We are pleased to announce the successful...
- Business09 October 2023
Adalvo announces successful Pivotal BE Study for Bosutinib Film-Coated Tablets
Adalvo is pleased to announce that the successful Pivotal BE Study for Bosutinib Film Coated Tablets has been completed, and we are currently preparing for our DCP submission, scheduled for November 2023. This product is used...
- Achievements06 October 2023
Adalvo's Padalvo Tournament Returns for a Grand Slam!
Adalvo are thrilled to announce that our much anticipated Padalvo tournament made a spectacular return this year. Padel, one of the world's fastest-growing sports, combines strategy, social interaction, and pure fun....
- Business04 October 2023
Adalvo Leads the Way in Diabetes Care with Unique Injectable and Oral Portfolio
Adalvo is thrilled to be making remarkable strides in the world of diabetic care. With an unwavering commitment to patient well-being, Adalvo proudly stands alone as the sole B2B company...
- Achievements02 October 2023
Adalvo nominated as finalist in six Global Generics & Biosimilars 2023 Awards
At Adalvo we are driven by our relentless passion and commitment to our partner network. We tirelessly strive for excellence in all of our endeavors, driven by a deep-rooted passion...
- Business29 September 2023
Adalvo Celebrates World Heart Day 2023
Adalvo proudly joins the global initiative to raise awareness on heart health, as the world marks World Heart Day on Friday, September 29th. Adalvo is deeply committed to cardiovascular health, and...
- Business27 September 2023
Adalvo CEO, Anil Okay nominated as finalist for CEO of the year award
Adalvo are honored to have been recognized by CPhI Pharma, where our CEO, Anil Okay, has been nominated as a finalist for the CEO of the Year Award! The CPhI...
- Sustainability22 September 2023
Adalvo Successfully Concludes International Week of Happiness
As the vibrant celebrations of International Week of Happiness come to a close, Adalvo reflects on a week filled with positivity, happiness, and well-being. From September 18th to 22nd, Adalvo...
- Business20 September 2023
Join Us For A Drink And Some Fun At CPhI 2023
Who says pharma events have to be all work and no play? Join us for an enjoyable break during CPhI 2023 on Wednesday, October 25th, starting at 16:00. Come socialize with Adalvo's bees and, if...
- Business18 September 2023
Adalvo and Lotus launch Gabapentin ER in South Korea
Adalvo is excited to announce the launch of Gabapentin ER 300/600 mg in South Korea, in collaboration with our sister company, Lotus. Our product is based on the reference...
- Business13 September 2023
Adalvo Recognizes Global Pain Awareness Month with Innovative Pain Portfolio
Adalvo proudly acknowledges September as Pain Awareness Month, joining the global community in raising awareness about the challenges faced by individuals dealing with chronic pain. With a strong commitment to improving the...
- Business07 September 2023
Adalvo announces successful DCP Submission for Empagliflozin Film-Coated Tablets
We are pleased to announce our successful DCP submission for Empagliflozin 25mg film-coated tablets, which was developed in collaboration with one of our strategic partners. Our product has been developed...
- Business04 September 2023
Adalvo and Cosmo partner up and launch Rifamycin SV MMX 200mg (Aemcolo®) in Europe, APAC, MENA and LATAM regions
Adalvo Ltd. (Adalvo) and Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced a collaboration agreement for Rifamycin SV with MMX® technology in Europe, Asia-Pacific (APAC), Middle East/North Africa (MENA) and Latin America (LATAM) regions. Under...